+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 19Years +
All Genders
ID06220773

Randomized Double-blind Study Evaluating BR1019A and BR1019B Combination Therapy in Adults with Essential Hypertension and Type 2 Diabetes Mellitus

Led by Boryung Pharmaceutical Co., Ltd · Updated on 2026-10-16

276

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of a combination therapy using BR1019A and BR1019B in patients who have both essential hypertension and type 2 diabetes mellitus. This phase 3 clinical trial aims to understand how this combination affects blood pressure and blood sugar control in this patient group. Participants will receive daily doses of investigational products including BR1019A, BR1019B, and BR1019C or their variants, taken once a day for 12 weeks. The study has multiple groups comparing different combinations of these drugs to observe their effects over this treatment period. During the trial, participants will be monitored for changes in systolic blood pressure and HbA1c levels from baseline at 12 weeks. Safety and efficacy assessments will be conducted throughout the treatment period. The total study duration extends up to December 2026, with participants expected to adhere to the daily medication schedule and visit the study sites as required for evaluations.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

Research Team

S

Shin-young Oh

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here